Preclinical gene therapy studies for hemophilia using adenoviral vectors

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 2, 2004, Pages 173-183

  Thorrez, Lieven ^a   VandenDriessche, Thierry ^a   Collen, Désiré ^a   Chuah, Marinee K L ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adenoviral vector; Gene therapy; Hemophilia A; Hemophilia B

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ACUTE DISEASE; BLOOD CLOTTING DISORDER; CHRONIC DISEASE; DISEASE MODEL; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; LIVER; MAMMAL CELL; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TOXICITY; TRANSGENE; VIRUS GENE;

ADENOVIRIDAE; ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; FACTOR IX; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A;

EID: 2342461788     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-825631     Document Type: Review

References (98)

1. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999;10:2091-2107
2. Hollestelle MJ, Thinnes T, Crain K, et al. Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001;86:855-861
3. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996;93:457-459
4. Teitel JM. Viral safety of haemophilia treatment products. Ann Med 2000;32:485-492
5. Evatt B. Creutzfeldt-Jakob disease and haemophilia: assessment of risk. Haemophilia 2000;6(suppl 1):94-99
6. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997;41:395-400
7. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995;10:119-121
8. Bi L, Sarkar R, Naas T, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996;88:3446-3450
9. Wang L, Zoppe M, Hackeng TM, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA 1997;94:11563-11566
10. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998;92:168-174
11. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood 1984;63:451-456
12. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 1989;86:10095-10099
13. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323
14. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503
15. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995;6:1575-1586
16. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988;6:616-629
17. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996;88:3846-3853
18. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999;94:3968-3975
19. National Institutes of Health Recombinant DNA Advisory Committee Assessment of adenoviral vector, safety and toxicity. Hum Gene Ther 2002;13:3-13
20. Armentano D, Sookdeo CC, Hehir KM, et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995;6:1343-1353
21. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther 1995;2:775-783
22. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-8943
23. Yeh P, Dedieu JF, Orsini C, et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996;70:559-565
24. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997;8:1275-1286
25. Fang B, Wang H, Gordon G, et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 1996;3:217-222
26. Gorziglia MI, Kadan MJ, Yei S, et al. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996;70:4173-4178
27. Ye X, Gao GP, Pabin C, Raper SE, Wilson JM. Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum Gene Ther 1998;9:2135-2142
28. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998;72:2022-2032
29. Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther 2001;3:329-336
30. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993;4:259-272
31. Hoeben RC, Fallaux FJ, Cramer SJ, et al. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995;85:2447-2454
32. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988;263:6352-6362
33. Connelly S, Smith TA, Dhir G, et al. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 1995;6:185-193
34. Connelly S, Gardner JM, McClelland A, Kaleko M. High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 1996;7:183-195
35. Connelly S, Gardner JM, Lyons RM, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood 1996;87:4671-4677
36. Connelly S, Andrews JL, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998;91:3273-3281
37. Connelly S, Andrews JL, Gallo-Penn AM, et al. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Thromb Haemost 1999;81:234-239
38. Gallo-Penn AM, Shirley PS, Andrews JL, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther 1999;10:1791-1802
39. Gallo-Penn AM, Shirley PS, Andrews JL, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001;97:107-113
40. Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH, Jr Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000;11:881-894
41. Lipshutz GS, Sarkar R, Flebbe-Rehwaldt L, Kazazian H, Gaensler KM. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA 1999;96:13324-13329
42. Braun T, Kayda D, Lyons RM, et al. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum Gene Ther 1999;10:2999-3011
43. Andrews JL, Shirley PS, Iverson WO, et al. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector. Hum Gene Ther 2002;13:1331-1336
44. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91:2353-2357
45. Walter J, You Q, Hagstrom JN, Sands M, High KA. Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci USA 1996;93:3056-3061
46. Schneider H, Adebakin S, Themis M, et al. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B. J Gene Med 1999;1:424-432
47. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998;91:784-790
48. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92:1401-1405
49. Fields PA, Kowalczyk DW, Arruda VR, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000;1:225-235
50. Lozier JN, Metzger ME, Donahue RE, Morgan RA. The rhesus macaque as an animal model for hemophilia B gene therapy. Blood 1999;93:1875-1881
51. Morral N, O'Neal WK, Rice K, et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002;13:143-154
52. Fang B, Eisensmith RC, Wang H, et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995;6:1039-1044
53. Smith TA, White BD, Gardner JM, Kaleko M, McClelland A. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 1996;3:496-502
54. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996;3:412-420
55. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999;96:12816-12821
56. Kochanek S, Clemens PR, Mitani K, et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996;93:5731-5736
57. Kochanek S. Development of high-capacity adenoviral vectors for gene therapy. Thromb Haemost 1999;82:547-551
58. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998;95:7866-7871
59. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18:180-183
60. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93:13565-13570
61. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997;71:3293-3298
62. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995;92:3854-3858
63. Clemens PR, Kochanek S, Sunada Y, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 1996;3:965-972
64. Chen HH, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997;94:1645-1650
65. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996;70:8944-8960
66. Zhang WW, Josephs SF, Zhou J, et al. Development and application of a minimal-adenoviral vector system for gene therapy of hemophilia A. Thromb Haemost 1999;82:562-571
67. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long- term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000;97:7482-7487
68. Balague C, Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000;95:820-828
69. Zou L, Zhou H, Pastore L, Yang K. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther 2000;2:105-113
70. Reddy PS, Sakhuja K, Ganesh S, et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002;5:63-73
71. Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003;101:1734-1743
72. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002;99:3923-3930
73. Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001;3:708-722
74. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998;95:11377-11382
75. Fang B, Andreason G, Hariharan M, et al. Pre-clinical efficacy and safety studies of a gutless adenovirus vector (MAXADFVIII) for treatment of haemophilia A. Thromb Haemost 2001;86:OC2490
76. VandenDriessche T, Collen D, Chuah MK. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther 2001;1:301-315
77. Brown BD, Shi CX, Powell S, et al. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 2004;103:804-810
78. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood 2002;100:1133-1140
79. Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol 2003;77:7689-7695
80. Ehrhardt A, Xu H, Dillow AM, et al. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 2003;102:2403-2411
81. Fechner H, Haack A, Wang H, et al. Expression of coxsackie adenovirus receptor and alpha v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999;6:1520-1535
82. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41
83. Yant SR, Ehrhardt A, Mikkelsen JG, et al. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002;20:999-1005
84. Shayakhmetov DM, Carlson CA, Stecher H, et al. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J Virol 2002;76:1135-1143
85. Van Damme A, Chuah MKL, Collen D, VandenDriessche T. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Semin Thromb Hemost 2004;30:185-196
86. Krougliak VA, Krougliak N, Eisensmith RC. Stabilization of transgenes delivered by recombinant adenovirus vectors through extrachromosomal replication. J Gene Med 2001;3:51-58
87. Kreppel F, Kochanek S. Episomally persisting high-capacity adenoviral vectors for prolonged transgene expression in proliferating cells. Mol Ther 2003;7:S192-S193
88. Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2000;2:223-232
89. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001;3:28-35
90. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398-401
91. Molinier-Frenkel V, Lengagne R, Gaden F, et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002;76:127-135
92. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999;10:1773-1781
93. De Geest BR, Van Linthout SA, Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen- presenting cells. Blood 2003;101:2551-2556
94. Schiedner G, Bloch W, Hertel S, et al. Hemodynamic response to intravenous adenovirus vector particles caused by systemic Kupffer cell mediated activation of endothelial cells. Mol Ther 2003;7:S7
95. Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8:341-348
96. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002;13:1887-1900
97. Smith T, Idamakanti N, Kylefjord H, et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002;5:770-779
98. Volpers C, Thirion C, Biermann V, et al. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 2003;77:2093-2104